Description

Heart failure with preserved EF (HFpEF) carries substantial morbidity and mortality, yet evidence-based treatments to improve outcomes are sorely lacking. Recently, the FDA made the unusual decision to approve sacubitril/valsartan for HFpEF despite a neutral trial with this agent. Similarly, while spironolactone’s major trial in HFpEF was not positive, guidelines have endorsed this therapy based on sub-group analyses. This podcast will explore why these decisions were made and whether these treatments should be considered for HFpEF patients.

Learning Objectives

• To review current treatment strategies for HFpEF
• To understand how neutral trials may still influence guidelines and practice

This program is NOT accredited.

Mainpro+ participants may earn certified credits by completing a Linking Learning Exercise.

Specialist participants may claim Section 2 credits (up to 2 credits per hour) following completion of a personal learning project (PLP) under Section 2: Self-Learning Activities within the MAINPORT ePortfolio. 

This program was developed by the Canadian Collaborative Research Network, a not-for-profit physician organization. 

No outside funding support was received for this program.